Network
Tripep collaborates with world-leading researchers and corporations so it can develop CDs rationally and cost-efficiently. This means that Tripep can safeguard the research on all its projects despite modest organizational resources. Tripep's professionals have extensive contact networks, based on their long-term sector experience, either as drug industry executives, clinical researchers or lecturers at universities and institutes of further education.
Networking Know-how
Tripep collaborates with world-leading researchers and corporations in each segment to be able to develop CDs rationally and cost-efficiently. Tripep signs collaboration agreements with partners that effectively complement its internal know-how. This means that Tripep can safeguard the research on all its projects despite modest organizational resources. Tripep has quickly succeeded in creating the right networked know-how for ChronVac-C®'s clinical development. Through its agreement with Inovio, Tripep has access to world-leading expertise in the in vivo electroporation segment, a technique used in DNA vaccination. Tripep has engaged Vecura AB for the production of ChronVac-C® and engaged Visionar AB to conduct toxicology studies. Both Vecura and Visionar have participated in the clinical development of DNA vaccines used on humans, and thus possess a unique combination of skills. Overall, this means that Tripep can conduct ChronVac-C®'s clinical development quickly and efficiently. The first phase I trial on ChronVac-C® will be conducted at the Karolinska University Hospital, Solna, Sweden, where Tripep has engaged leading clinicians in the treatment of hepatitis C virus infections.
Tripep collaborates with research teams at two of Sweden's most renowned research institutions: the Karolinska Institute and the University of Uppsala. Experimental research is conducted at university laboratories, while the more industrial research is conducted at Tripep's laboratories at the Novum Research Park in Huddinge, near Stockholm, Sweden.